APA (7th ed.) Citation

Pink, A. E., Houghton, J., White, H., Schiavo, S., Piketty, C., Ulianov, L., . . . Puelles, J. (2026). Comparing the Efficacy and Safety of Nemolizumab Versus Anti-interleukin Monoclonal Antibody Therapies in Combination with Topical Treatments for Moderate-to-Severe Atopic Dermatitis Using Network Meta-analysis. Dermatology & Therapy, 16(2), 1347. https://doi.org/10.1007/s13555-025-01647-0

Chicago Style (17th ed.) Citation

Pink, Andrew E., et al. "Comparing the Efficacy and Safety of Nemolizumab Versus Anti-interleukin Monoclonal Antibody Therapies in Combination with Topical Treatments for Moderate-to-Severe Atopic Dermatitis Using Network Meta-analysis." Dermatology & Therapy 16, no. 2 (2026): 1347. https://doi.org/10.1007/s13555-025-01647-0.

MLA (9th ed.) Citation

Pink, Andrew E., et al. "Comparing the Efficacy and Safety of Nemolizumab Versus Anti-interleukin Monoclonal Antibody Therapies in Combination with Topical Treatments for Moderate-to-Severe Atopic Dermatitis Using Network Meta-analysis." Dermatology & Therapy, vol. 16, no. 2, 2026, p. 1347, https://doi.org/10.1007/s13555-025-01647-0.